We then validated PAtrace in phantom, in vitro, and in vivo PA imaging environments for both spectral unmixing accuracy and targeting efficacy with a folate receptor alpha-positive (FRα+) ovarian cancer model. Here, FOLR1 is linked to ovarian carcinoma.